BRCA2 Mutation

Evaluating Cascade Communication Methods

Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy

Radical Fimbriectomy for Young BRCA Mutation Carriers

Combination Therapy in Cancers With Mutations in DNA Repair Genes

BRCA Founder OutReach (BFOR) Study

Functional Analysis of BRCAness

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

BRCA Mutation Carriers' Platform a Multicenter Study

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

Genetic Education in BRCA Families